MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD DisclosureITEM 7.01
REGULATION FD DISCLOSURE.
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
On April 18, 2018, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release regarding antibody program results featured in three presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
Press Release Dated April 18, 2018 |
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm ADDITIONAL EXHIBITS ex99-1 Exhibit 99.1 MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting – Interim results from Phase 1 clinical trial of MVT-1075,…To view the full exhibit click here
